Search

Your search keyword '"Chételat, Gaël"' showing total 1,020 results
Start Over Author "Chételat, Gaël" Publication Year Range Last 50 years
1,020 results on '"Chételat, Gaël"'

5. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder

Author

Adamson, Chris, Adler, Sophie, Alexander-Bloch, Aaron F., Anagnostou, Evdokia, Anderson, Kevin M., Areces-Gonzalez, Ariosky, Astle, Duncan E., Auyeung, Bonnie, Ayub, Muhammad, Bae, Jong Bin, Ball, Gareth, Baron-Cohen, Simon, Beare, Richard, Bedford, Saashi A., Benegal, Vivek, Bethlehem, Richard A.I., Beyer, Frauke, Blangero, John, Cábez, Manuel Blesa, Boardman, James P., Borzage, Matthew, Bosch-Bayard, Jorge F., Bourke, Niall, Bullmore, Edward T., Calhoun, Vince D., Chakravarty, Mallar M., Chen, Christina, Chertavian, Casey, Chetelat, Gaël, Chong, Yap S., Corvin, Aiden, Costantino, Manuela, Courchesne, Eric, Crivello, Fabrice, Cropley, Vanessa L., Crosbie, Jennifer, Crossley, Nicolas, Delarue, Marion, Delorme, Richard, Desrivieres, Sylvane, Devenyi, Gabriel, Di Biase, Maria A., Dolan, Ray, Donald, Kirsten A., Donohoe, Gary, Dorfschmidt, Lena, Dunlop, Katharine, Edwards, Anthony D., Elison, Jed T., Ellis, Cameron T., Elman, Jeremy A., Eyler, Lisa, Fair, Damien A., Fletcher, Paul C., Fonagy, Peter, Franz, Carol E., Galan-Garcia, Lidice, Gholipour, Ali, Giedd, Jay, Gilmore, John H., Glahn, David C., Goodyer, Ian M., Grant, P.E., Groenewold, Nynke A., Gudapati, Shreya, Gunning, Faith M., Gur, Raquel E., Gur, Ruben C., Hammill, Christopher F., Hansson, Oskar, Hedden, Trey, Heinz, Andreas, Henson, Richard N., Heuer, Katja, Hoare, Jacqueline, Holla, Bharath, Holmes, Avram J., Huang, Hao, Ipser, Jonathan, Jack, Clifford R., Jr., Jackowski, Andrea P., Jia, Tianye, Jones, David T., Jones, Peter B., Kahn, Rene S., Karlsson, Hasse, Karlsson, Linnea, Kawashima, Ryuta, Kelley, Elizabeth A., Kern, Silke, Kim, Ki-Woong, Kitzbichler, Manfred G., Kremen, William S., Lalonde, François, Landeau, Brigitte, Lerch, Jason, Lewis, John D., Li, Jiao, Liao, Wei, Liston, Conor, Lombardo, Michael V., Lv, Jinglei, Mallard, Travis T., Marcelis, Machteld, Mathias, Samuel R., Mazoyer, Bernard, McGuire, Philip, Meaney, Michael J., Mechelli, Andrea, Misic, Bratislav, Morgan, Sarah E., Mothersill, David, Ortinau, Cynthia, Ossenkoppele, Rik, Ouyang, Minhui, Palaniyappan, Lena, Paly, Leo, Pan, Pedro M., Pantelis, Christos, Park, Min Tae M., Paus, Tomas, Pausova, Zdenka, Paz-Linares, Deirel, Binette, Alexa Pichet, Pierce, Karen, Qian, Xing, Qiu, Anqi, Raznahan, Armin, Rittman, Timothy, Rodrigue, Amanda, Rollins, Caitlin K., Romero-Garcia, Rafael, Ronan, Lisa, Rosenberg, Monica D., Rowitch, David H., Salum, Giovanni A., Satterthwaite, Theodore D., Schaare, H. Lina, Schabdach, Jenna, Schachar, Russell J., Schöll, Michael, Schultz, Aaron P., Seidlitz, Jakob, Sharp, David, Shinohara, Russell T., Skoog, Ingmar, Smyser, Christopher D., Sperling, Reisa A., Stein, Dan J., Stolicyn, Aleks, Suckling, John, Sullivan, Gemma, Thyreau, Benjamin, Toro, Roberto, Traut, Nicolas, Tsvetanov, Kamen A., Turk-Browne, Nicholas B., Tuulari, Jetro J., Tzourio, Christophe, Vachon-Presseau, Étienne, Valdes-Sosa, Mitchell J., Valdes-Sosa, Pedro A., Valk, Sofie L., van Amelsvoort, Therese, Vandekar, Simon N., Vasung, Lana, Vértes, Petra E., Victoria, Lindsay W., Villeneuve, Sylvia, Villringer, Arno, Vogel, Jacob W., Wagstyl, Konrad, Wang, Yin-Shan S., Warfield, Simon K., Warrier, Varun, Westman, Eric, Westwater, Margaret L., Whalley, Heather C., White, Simon R., Witte, A. Veronica, Yang, Ning, Yeo, B.T. Thomas, Yun, Hyuk Jin, Zalesky, Andrew, Zar, Heather J., Zettergren, Anna, Zhou, Juan H., Ziauddeen, Hisham, Zimmerman, Dabriel, Zugman, Andre, Zuo, Xi-Nian N., Ho, Natalie C.W., Nogovitsyn, Nikita, Metzak, Paul, Ballester, Pedro L., Hassel, Stefanie, Rotzinger, Susan, Poppenk, Jordan, Lam, Raymond W., Taylor, Valerie H., Milev, Roumen, Frey, Benicio N., Harkness, Kate L., Addington, Jean, and Kennedy, Sidney H.

Published
2024
Full Text
View/download PDF

6. Current directions in tau research: Highlights from Tau 2020

Author

Sexton, Claire, Snyder, Heather, Beher, Dirk, Boxer, Adam L, Brannelly, Pat, Brion, Jean‐Pierre, Buée, Luc, Cacace, Angela M, Chételat, Gaël, Citron, Martin, DeVos, Sarah L, Diaz, Kristophe, Feldman, Howard H, Frost, Bess, Goate, Alison M, Gold, Michael, Hyman, Bradley, Johnson, Keith, Karch, Celeste M, Kerwin, Diana R, Koroshetz, Walter J, Litvan, Irene, Morris, Huw R, Mummery, Catherine J, Mutamba, James, Patterson, Marc C, Quiroz, Yakeel T, Rabinovici, Gil D, Rommel, Amy, Shulman, Melanie B, Toledo‐Sherman, Leticia M, Weninger, Stacie, Wildsmith, Kristin R, Worley, Susan L, and Carrillo, Maria C

Subjects
Biomedical and Clinical Sciences, Biological Psychology, Clinical Sciences, Neurosciences, Psychology, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Alzheimer's Disease, Dementia, Aging, Brain Disorders, Neurodegenerative, Alzheimer Disease, Biomarkers, Cognitive Dysfunction, Drug Discovery, Humans, tau Proteins, Alzheimer's, biomarkers, neurodegeneration, tau, therapeutics, Geriatrics, Clinical sciences, Biological psychology
Abstract

Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.

Published
2022

7. Current directions in tau research: Highlights from Tau 2020.

Author

Sexton, Claire, Snyder, Heather, Beher, Dirk, Boxer, Adam L, Brannelly, Pat, Brion, Jean-Pierre, Buée, Luc, Cacace, Angela M, Chételat, Gaël, Citron, Martin, DeVos, Sarah L, Diaz, Kristophe, Feldman, Howard H, Frost, Bess, Goate, Alison M, Gold, Michael, Hyman, Bradley, Johnson, Keith, Karch, Celeste M, Kerwin, Diana R, Koroshetz, Walter J, Litvan, Irene, Morris, Huw R, Mummery, Catherine J, Mutamba, James, Patterson, Marc C, Quiroz, Yakeel T, Rabinovici, Gil D, Rommel, Amy, Shulman, Melanie B, Toledo-Sherman, Leticia M, Weninger, Stacie, Wildsmith, Kristin R, Worley, Susan L, and Carrillo, Maria C

Subjects
Alzheimer's, biomarkers, neurodegeneration, tau, therapeutics, Brain Disorders, Aging, Acquired Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Neurosciences, Dementia, Neurodegenerative, Geriatrics, Clinical Sciences
Abstract

Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.

Published
2021

8. Hippocampal subfield volumetry from structural isotropic 1 mm3 MRI scans: A note of caution

Author

Wisse, Laura EM, Chételat, Gaël, Daugherty, Ana M, de Flores, Robin, la Joie, Renaud, Mueller, Susanne G, Stark, Craig EL, Wang, Lei, Yushkevich, Paul A, Berron, David, Raz, Naftali, Bakker, Arnold, Olsen, Rosanna K, and Carr, Valerie A

Subjects
Biomedical and Clinical Sciences, Neurosciences, Biomedical Imaging, Bioengineering, Aging, Hippocampus, Humans, Magnetic Resonance Imaging, Organ Size, mm(3), FreeSurfer, hippocampal subfields, MRI, volumetry, 1 mm3, Cognitive Sciences, Experimental Psychology, Biological psychology, Cognitive and computational psychology
Abstract

Spurred by availability of automatic segmentation software, in vivo MRI investigations of human hippocampal subfield volumes have proliferated in the recent years. However, a majority of these studies apply automatic segmentation to MRI scans with approximately 1 × 1 × 1 mm3 resolution, a resolution at which the internal structure of the hippocampus can rarely be visualized. Many of these studies have reported contradictory and often neurobiologically surprising results pertaining to the involvement of hippocampal subfields in normal brain function, aging, and disease. In this commentary, we first outline our concerns regarding the utility and validity of subfield segmentation on 1 × 1 × 1 mm3 MRI for volumetric studies, regardless of how images are segmented (i.e., manually or automatically). This image resolution is generally insufficient for visualizing the internal structure of the hippocampus, particularly the stratum radiatum lacunosum moleculare, which is crucial for valid and reliable subfield segmentation. Second, we discuss the fact that automatic methods that are employed most frequently to obtain hippocampal subfield volumes from 1 × 1 × 1 mm3 MRI have not been validated against manual segmentation on such images. For these reasons, we caution against using volumetric measurements of hippocampal subfields obtained from 1 × 1 × 1 mm3 images.

Published
2021

13. Dementia prevention in memory clinics: recommendations from the European task force for brain health services

Author

Frisoni, Giovanni B., Altomare, Daniele, Ribaldi, Federica, Villain, Nicolas, Brayne, Carol, Mukadam, Naaheed, Abramowicz, Marc, Barkhof, Frederik, Berthier, Marcelo, Bieler-Aeschlimann, Melanie, Blennow, Kaj, Brioschi Guevara, Andrea, Carrera, Emmanuel, Chételat, Gaël, Csajka, Chantal, Demonet, Jean-François, Dodich, Alessandra, Garibotto, Valentina, Georges, Jean, Hurst, Samia, Jessen, Frank, Kivipelto, Miia, Llewellyn, David J., McWhirter, Laura, Milne, Richard, Minguillón, Carolina, Miniussi, Carlo, Molinuevo, José Luis, Nilsson, Peter M., Noyce, Alastair, Ranson, Janice M., Grau-Rivera, Oriol, Schott, Jonathan M., Solomon, Alina, Stephen, Ruth, van der Flier, Wiesje, van Duijn, Cornelia, Vellas, Bruno, Visser, Leonie N.C., Cummings, Jeffrey L., Scheltens, Philip, Ritchie, Craig, and Dubois, Bruno

Published
2023
Full Text
View/download PDF

14. The Effect of Mindfulness-based Programs on Cognitive Function in Adults: A Systematic Review and Meta-analysis

Author

Whitfield, Tim, Barnhofer, Thorsten, Acabchuk, Rebecca, Cohen, Avi, Lee, Michael, Schlosser, Marco, Arenaza-Urquijo, Eider M., Böttcher, Adriana, Britton, Willoughby, Coll-Padros, Nina, Collette, Fabienne, Chételat, Gaël, Dautricourt, Sophie, Demnitz-King, Harriet, Dumais, Travis, Klimecki, Olga, Meiberth, Dix, Moulinet, Inès, Müller, Theresa, Parsons, Elizabeth, Sager, Lauren, Sannemann, Lena, Scharf, Jodi, Schild, Ann-Katrin, Touron, Edelweiss, Wirth, Miranka, Walker, Zuzana, Moitra, Ethan, Lutz, Antoine, Lazar, Sara W., Vago, David, and Marchant, Natalie L.

Published
2022
Full Text
View/download PDF

15. Progress update from the hippocampal subfields group

Author

Olsen, Rosanna K, Carr, Valerie A, Daugherty, Ana M, La Joie, Renaud, Amaral, Robert SC, Amunts, Katrin, Augustinack, Jean C, Bakker, Arnold, Bender, Andrew R, Berron, David, Boccardi, Marina, Bocchetta, Martina, Burggren, Alison C, Chakravarty, M Mallar, Chételat, Gaël, de Flores, Robin, DeKraker, Jordan, Ding, Song‐Lin, Geerlings, Mirjam I, Huang, Yushan, Insausti, Ricardo, Johnson, Elliott G, Kanel, Prabesh, Kedo, Olga, Kennedy, Kristen M, Keresztes, Attila, Lee, Joshua K, Lindenberger, Ulman, Mueller, Susanne G, Mulligan, Elizabeth M, Ofen, Noa, Palombo, Daniela J, Pasquini, Lorenzo, Pluta, John, Raz, Naftali, Rodrigue, Karen M, Schlichting, Margaret L, Shing, Yee Lee, Stark, Craig EL, Steve, Trevor A, Suthana, Nanthia A, Wang, Lei, Werkle‐Bergner, Markus, Yushkevich, Paul A, Yu, Qijing, Wisse, Laura EM, and Group, Hippocampal Subfields

Subjects
Biological Psychology, Biomedical and Clinical Sciences, Neurosciences, Psychology, Hippocampus, Volumetry, Human, Neuroimaging, Structural imaging, Neuroanatomy, Histology, Cytoarchitecture, ex vivo, Hippocampal Subfields Group, ex vivo, Genetics, Biological psychology
Abstract

IntroductionHeterogeneity of segmentation protocols for medial temporal lobe regions and hippocampal subfields on in vivo magnetic resonance imaging hinders the ability to integrate findings across studies. We aim to develop a harmonized protocol based on expert consensus and histological evidence.MethodsOur international working group, funded by the EU Joint Programme-Neurodegenerative Disease Research (JPND), is working toward the production of a reliable, validated, harmonized protocol for segmentation of medial temporal lobe regions. The working group uses a novel postmortem data set and online consensus procedures to ensure validity and facilitate adoption.ResultsThis progress report describes the initial results and milestones that we have achieved to date, including the development of a draft protocol and results from the initial reliability tests and consensus procedures.DiscussionA harmonized protocol will enable the standardization of segmentation methods across laboratories interested in medial temporal lobe research worldwide.

Published
2019

16. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Author

Babulal, Ganesh M, Quiroz, Yakeel T, Albensi, Benedict C, Arenaza-Urquijo, Eider, Astell, Arlene J, Babiloni, Claudio, Bahar-Fuchs, Alex, Bell, Joanne, Bowman, Gene L, Brickman, Adam M, Chételat, Gaël, Ciro, Carrie, Cohen, Ann D, Dilworth-Anderson, Peggye, Dodge, Hiroko H, Dreux, Simone, Edland, Steven, Esbensen, Anna, Evered, Lisbeth, Ewers, Michael, Fargo, Keith N, Fortea, Juan, Gonzalez, Hector, Gustafson, Deborah R, Head, Elizabeth, Hendrix, James A, Hofer, Scott M, Johnson, Leigh A, Jutten, Roos, Kilborn, Kerry, Lanctôt, Krista L, Manly, Jennifer J, Martins, Ralph N, Mielke, Michelle M, Morris, Martha Clare, Murray, Melissa E, Oh, Esther S, Parra, Mario A, Rissman, Robert A, Roe, Catherine M, Santos, Octavio A, Scarmeas, Nikolaos, Schneider, Lon S, Schupf, Nicole, Sikkes, Sietske, Snyder, Heather M, Sohrabi, Hamid R, Stern, Yaakov, Strydom, Andre, Tang, Yi, Terrera, Graciela Muniz, Teunissen, Charlotte, Melo van Lent, Debora, Weinborn, Michael, Wesselman, Linda, Wilcock, Donna M, Zetterberg, Henrik, O'Bryant, Sid E, and International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association

Subjects
International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association, Humans, Alzheimer Disease, Biomedical Research, Aged, Continental Population Groups, Ethnic Groups, Healthcare Disparities, Biomarkers, Alzheimer's disease, Alzheimer's related dementias, Diversity, Ethnicity, Ethnoracial, Translational, Underserved, Geriatrics, Clinical Sciences, Neurosciences
Abstract

Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross-PIA white paper that provides both a concise "state-of-the-science" report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.

Published
2019

18. Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging

Author

Gerardin, Emilie, Chételat, Gaël, Chupin, Marie, Cuingnet, Rémi, Desgranges, Béatrice, Kim, Ho-Sung, Niethammer, Marc, Dubois, Bruno, Lehéricy, Stéphane, Garnero, Line, Eustache, Francis, and Colliot, Olivier

Subjects
Computer Science - Computer Vision and Pattern Recognition, Quantitative Biology - Neurons and Cognition, Statistics - Machine Learning
Abstract

We describe a new method to automatically discriminate between patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI) and elderly controls, based on multidimensional classification of hippocampal shape features. This approach uses spherical harmonics (SPHARM) coefficients to model the shape of the hippocampi, which are segmented from magnetic resonance images (MRI) using a fully automatic method that we previously developed. SPHARM coefficients are used as features in a classification procedure based on support vector machines (SVM). The most relevant features for classification are selected using a bagging strategy. We evaluate the accuracy of our method in a group of 23 patients with AD (10 males, 13 females, age $\pm$ standard-deviation (SD) = 73 $\pm$ 6 years, mini-mental score (MMS) = 24.4 $\pm$ 2.8), 23 patients with amnestic MCI (10 males, 13 females, age $\pm$ SD = 74 $\pm$ 8 years, MMS = 27.3 $\pm$ 1.4) and 25 elderly healthy controls (13 males, 12 females, age $\pm$ SD = 64 $\pm$ 8 years), using leave-one-out cross-validation. For AD vs controls, we obtain a correct classification rate of 94%, a sensitivity of 96%, and a specificity of 92%. For MCI vs controls, we obtain a classification rate of 83%, a sensitivity of 83%, and a specificity of 84%. This accuracy is superior to that of hippocampal volumetry and is comparable to recently published SVM-based whole-brain classification methods, which relied on a different strategy. This new method may become a useful tool to assist in the diagnosis of Alzheimer's disease., Comment: Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database

Published
2017
Full Text
View/download PDF

19. Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia

Author

Lorenzini, Luigi, Ingala, Silvia, Wottschel, Viktor, Wink, Alle Meije, Mutsaerts, Henk JMM, Haller, Sven, Blennow, Kaj, O'Brien, John T., Frisoni, B. Giovanni, Chételat, Gael, Payoux, Pierre, Martinez-Lage, Pablo, Waldman, Adam, Wardlaw, Joanna, Ritchie, Craig, Gispert, Juan Domingo, Visser, Pieter Jelle, Scheltens, Philip, Barkhof, Frederik, and Tijms, Betty M.

Published
2022
Full Text
View/download PDF

20. The Open-Access European Prevention of Alzheimer’s Dementia (EPAD) MRI dataset and processing workflow

Author

Lorenzini, Luigi, Ingala, Silvia, Wink, Alle Meije, Kuijer, Joost P.A., Wottschel, Viktor, Dijsselhof, Mathijs, Sudre, Carole H., Haller, Sven, Molinuevo, José Luis, Gispert, Juan Domingo, Cash, David M., Thomas, David L., Vos, Sjoerd B., Prados, Ferran, Petr, Jan, Wolz, Robin, Palombit, Alessandro, Schwarz, Adam J., Chételat, Gaël, Payoux, Pierre, Di Perri, Carol, Wardlaw, Joanna M., Frisoni, Giovanni B., Foley, Christopher, Fox, Nick C., Ritchie, Craig, Pernet, Cyril, Waldman, Adam, Barkhof, Frederik, and Mutsaerts, Henk J.M.M.

Published
2022
Full Text
View/download PDF

23. Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

Author

Bergeron, David, Gorno‐Tempini, Maria L, Rabinovici, Gil D, Santos‐Santos, Miguel A, Seeley, William, Miller, Bruce L, Pijnenburg, Yolande, Keulen, M Antoinette, Groot, Colin, van Berckel, Bart NM, van der Flier, Wiesje M, Scheltens, Philip, Rohrer, Jonathan D, Warren, Jason D, Schott, Jonathan M, Fox, Nick C, Sanchez‐Valle, Raquel, Grau‐Rivera, Oriol, Gelpi, Ellen, Seelaar, Harro, Papma, Janne M, van Swieten, John C, Hodges, John R, Leyton, Cristian E, Piguet, Olivier, Rogalski, Emily J, Mesulam, Marsel M, Koric, Lejla, Kristensen, Nora, Pariente, Jeéreémie, Dickerson, Bradford, Mackenzie, Ian R, Hsiung, Ging‐Yuek R, Belliard, Serge, Irwin, David J, Wolk, David A, Grossman, Murray, Jones, Matthew, Harris, Jennifer, Mann, David, Snowden, Julie S, Chrem‐Mendez, Patricio, Calandri, Ismael L, Amengual, Alejandra A, Miguet‐Alfonsi, Carole, Magnin, Eloi, Magnani, Giuseppe, Santangelo, Roberto, Deramecourt, Vincent, Pasquier, Florence, Mattsson, Niklas, Nilsson, Christer, Hansson, Oskar, Keith, Julia, Masellis, Mario, Black, Sandra E, Matías‐Guiu, Jordi A, Cabrera‐Martin, María‐Nieves, Paquet, Claire, Dumurgier, Julien, Teichmann, Marc, Sarazin, Marie, Bottlaender, Michel, Dubois, Bruno, Rowe, Christopher C, Villemagne, Victor L, Vandenberghe, Rik, Granadillo, Elias, Teng, Edmond, Mendez, Mario, Meyer, Philipp T, Frings, Lars, Lleó, Alberto, Blesa, Rafael, Fortea, Juan, Seo, Sang Won, Diehl‐Schmid, Janine, Grimmer, Timo, Frederiksen, Kristian Steen, Sánchez‐Juan, Pascual, Chételat, Gaël, Jansen, Willemijn, Bouchard, Rémi W, Laforce, Robert Jr, Visser, Pieter Jelle, and Ossenkoppele, Rik

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Dementia, Rare Diseases, Aging, Neurodegenerative, Brain Disorders, Frontotemporal Dementia (FTD), Clinical Research, Aphasia, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Alzheimer's Disease Related Dementias (ADRD), Genetics, Alzheimer's Disease, 4.2 Evaluation of markers and technologies, Aetiology, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, Neurological, Age Factors, Aged, Aged, 80 and over, Amyloid beta-Peptides, Aphasia, Primary Progressive, Apolipoproteins E, Brain, Female, Genotype, Humans, Male, Middle Aged, Prevalence, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants.MethodsWe conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models.ResultsAmyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p

Published
2018

24. Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial

Author

Whitfield, Tim, Demnitz-King, Harriet, Schlosser, Marco, Barnhofer, Thorsten, Frison, Eric, Coll-Padros, Nina, Dautricourt, Sophie, Requier, Florence, Delarue, Marion, Gonneaud, Julie, Klimecki, Olga M., Lutz, Antoine, Paly, Léo, Salmon, Eric, Schild, Ann-Katrin, Walker, Zuzana, Jessen, Frank, Chételat, Gaël, Collette, Fabienne, Wirth, Miranka, and Marchant, Natalie L.

Published
2022
Full Text
View/download PDF

27. Association of quality of life with structural, functional and molecular brain imaging in community-dwelling older adults

Author

Ourry, Valentin, Gonneaud, Julie, Landeau, Brigitte, Moulinet, Inès, Touron, Edelweiss, Dautricourt, Sophie, Le Du, Gwendoline, Mézenge, Florence, André, Claire, Bejanin, Alexandre, Sherif, Siya, Marchant, Natalie L., Paly, Léo, Poisnel, Géraldine, Vivien, Denis, Chocat, Anne, Quillard, Anne, Ferrand Devouge, Eglantine, de la Sayette, Vincent, Rauchs, Géraldine, Arenaza-Urquijo, Eider M., and Chételat, Gaël

Published
2021
Full Text
View/download PDF

28. Alzheimer's disease

Author

Scheltens, Philip, De Strooper, Bart, Kivipelto, Miia, Holstege, Henne, Chételat, Gael, Teunissen, Charlotte E, Cummings, Jeffrey, and van der Flier, Wiesje M

Published
2021
Full Text
View/download PDF

33. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

Author

Chételat, Gaël, Arbizu, Javier, Barthel, Henryk, Garibotto, Valentina, Law, Ian, Morbelli, Silvia, van de Giessen, Elsmarieke, Agosta, Federica, Barkhof, Frederik, Brooks, David J, Carrillo, Maria C, Dubois, Bruno, Fjell, Anders M, Frisoni, Giovanni B, Hansson, Oskar, Herholz, Karl, Hutton, Brian F, Jack, Clifford R, Jr, Lammertsma, Adriaan A, Landau, Susan M, Minoshima, Satoshi, Nobili, Flavio, Nordberg, Agneta, Ossenkoppele, Rik, Oyen, Wim J G, Perani, Daniela, Rabinovici, Gil D, Scheltens, Philip, Villemagne, Victor L, Zetterberg, Henrik, and Drzezga, Alexander

Published
2020
Full Text
View/download PDF

36. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease

Author

Chételat, Gaël, Ossenkoppele, Rik, Villemagne, Victor L, Perrotin, Audrey, Landeau, Brigitte, Mézenge, Florence, Jagust, William J, Dore, Vincent, Miller, Bruce L, Egret, Stéphanie, Seeley, William W, van der Flier, Wiesje M, La Joie, Renaud, Ames, David, van Berckel, Bart NM, Scheltens, Philip, Barkhof, Frederik, Rowe, Christopher C, Masters, Colin L, de La Sayette, Vincent, Bouwman, Femke, and Rabinovici, Gil D

Subjects
Biological Psychology, Psychology, Acquired Cognitive Impairment, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Rare Diseases, Brain Disorders, Alzheimer's Disease, Neurosciences, Biomedical Imaging, Dementia, Aging, Neurodegenerative, 4.1 Discovery and preclinical testing of markers and technologies, 2.1 Biological and endogenous factors, 4.2 Evaluation of markers and technologies, Aetiology, Detection, screening and diagnosis, Neurological, Aged, Alzheimer Disease, Amnesia, Atrophy, Female, Follow-Up Studies, Gyrus Cinguli, Hippocampus, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Positron-Emission Tomography, amyloid, PET, MRI, Alzheimer's disease, retrosplenial posterior cingulate, Alzheimer’s disease, Medical and Health Sciences, Psychology and Cognitive Sciences, Neurology & Neurosurgery, Biomedical and clinical sciences, Health sciences
Abstract

See O'Sullivan and Vann (doi:10.1093/aww166) for a scientific commentary on this article.About 15% of patients clinically diagnosed with Alzheimer's disease do not show high tracer retention on amyloid positon emission tomography imaging. The present study investigates clinical and demographic features, patterns of brain atrophy and hypometabolism and longitudinal clinical trajectories of these patients. Forty amyloid-negative patients carrying a pre-scan diagnosis of Alzheimer's disease dementia from four centres were included (11/29 females/males; mean age = 67 ± 9). Detailed clinical histories, including the clinical diagnoses before and after the amyloid scan and at follow-up, were collected. Patients were classified according to their pre-scan clinical phenotype as amnestic (memory predominant), non-amnestic (predominant language, visuospatial or frontal symptoms), or non-specific (diffuse cognitive deficits). Demographic, clinical, neuropsychological, magnetic resonance imaging and (18)F-fluorodeoxyglucose positon emission tomography data were compared to 27 amyloid-positive typical Alzheimer's disease cases (14/13 females/males; mean age = 71 ± 10) and 29 amyloid-negative controls (15/14 females/males; mean age = 69 ± 12) matched for age, gender and education. There were 21 amnestic, 12 non-amnestic, and seven non-specific amyloid-negative Alzheimer's disease cases. Amyloid-negative subgroups did not differ in age, gender or education. After the amyloid scan, clinicians altered the diagnosis in 68% of amyloid-negative patients including 48% of amnestic versus 94% of non-amnestic and non-specific cases. Amnestic amyloid-negative cases were most often reclassified as frontotemporal dementia, non-amnestic as frontotemporal dementia or corticobasal degeneration, and non-specific as dementia with Lewy bodies or unknown diagnosis. The longer-term clinical follow-up was consistent with the post-scan diagnosis in most cases (90%), including in amnestic amyloid-negative cases whose post-positon emission tomography diagnosis remained Alzheimer's disease. While the non-amnestic and non-specific amyloid-negative cases usually showed patterns of atrophy and hypometabolism suggestive of another degenerative disorder, the amnestic amyloid-negative cases had subtle atrophy and hypometabolism, restricted to the retrosplenial/posterior cingulate cortex. Patients with a negative amyloid positon emission tomography scan following an initial clinical diagnosis of Alzheimer's disease have heterogeneous clinical presentations and neuroimaging profiles; a majority showed a clinical progression that was consistent with a neurodegenerative condition. In contrast, in the subgroup of amnestic amyloid-negative cases, the clinical presentation and follow-up usually remained consistent with Alzheimer's disease. An alternative diagnosis was not made in about half of the amnestic amyloid-negative cases, highlighting the need for a clinical framework and terminology to define these patients, who may have underlying limbic-predominant, non-amyloid-related pathologies.

Published
2016

37. Suspected non-Alzheimer disease pathophysiology — concept and controversy

Author

Jack, Clifford R, Knopman, David S, Chételat, Gaël, Dickson, Dennis, Fagan, Anne M, Frisoni, Giovanni B, Jagust, William, Mormino, Elizabeth C, Petersen, Ronald C, Sperling, Reisa A, van der Flier, Wiesje M, Villemagne, Victor L, Visser, Pieter J, and Vos, Stephanie JB

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Neurodegenerative, Dementia, Clinical Research, Aging, Alzheimer's Disease, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Brain Disorders, 2.1 Biological and endogenous factors, Aetiology, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Neurological, Alzheimer Disease, Biomarkers, Brain, Cognition Disorders, Humans, Clinical sciences
Abstract

Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegeneration are abnormal. The term SNAP has been applied to clinically normal individuals (who do not meet criteria for either mild cognitive impairment or dementia) and to individuals with mild cognitive impairment, but is applicable to any amyloid-negative, neurodegeneration-positive individual regardless of clinical status, except when the pathology underlying neurodegeneration can be reliably inferred from the clinical presentation. SNAP is present in ∼23% of clinically normal individuals aged >65 years and in ∼25% of mildly cognitively impaired individuals. APOE*ε4 is underrepresented in individuals with SNAP compared with amyloid-positive individuals. Clinically normal and mildly impaired individuals with SNAP have worse clinical and/or cognitive outcomes than individuals with normal levels of neurodegeneration and amyloid-β biomarkers. In this Perspectives article, we describe the available data on SNAP and address topical controversies in the field.

Published
2016

38. Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis

Author

Ossenkoppele, Rik, Jansen, Willemijn J, Rabinovici, Gil D, Knol, Dirk L, van der Flier, Wiesje M, van Berckel, Bart NM, Scheltens, Philip, Visser, Pieter Jelle, Verfaillie, Sander CJ, Zwan, Marissa D, Adriaanse, Sofie M, Lammertsma, Adriaan A, Barkhof, Frederik, Jagust, William J, Miller, Bruce L, Rosen, Howard J, Landau, Susan M, Villemagne, Victor L, Rowe, Christopher C, Lee, Dong Y, Na, Duk L, Seo, Sang W, Sarazin, Marie, Roe, Catherine M, Sabri, Osama, Barthel, Henryk, Koglin, Norman, Hodges, John, Leyton, Cristian E, Vandenberghe, Rik, van Laere, Koen, Drzezga, Alexander, Forster, Stefan, Grimmer, Timo, Sánchez-Juan, Pascual, Carril, Jose M, Mok, Vincent, Camus, Vincent, Klunk, William E, Cohen, Ann D, Meyer, Philipp T, Hellwig, Sabine, Newberg, Andrew, Frederiksen, Kristian S, Fleisher, Adam S, Mintun, Mark A, Wolk, David A, Nordberg, Agneta, Rinne, Juha O, Chételat, Gaël, Lleo, Alberto, Blesa, Rafael, Fortea, Juan, Madsen, Karine, Rodrigue, Karen M, and Brooks, David J

Subjects
Health Services and Systems, Health Sciences, Genetics, Acquired Cognitive Impairment, Clinical Research, Neurodegenerative, Alzheimer's Disease, Brain Disorders, Aging, Biomedical Imaging, Neurosciences, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Dementia, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Neurological, Adult, Age Factors, Aged, Aged, 80 and over, Amyloid beta-Peptides, Apolipoprotein E4, Brain, Female, Genotype, Humans, Male, Middle Aged, Positron-Emission Tomography, Prevalence, Risk Factors, Amyloid PET Study Group, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceAmyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.Data sourcesThe MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.Study selectionCase reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.Data extraction and synthesisData were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).Main outcomes and measuresEstimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method.ResultsThe likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P

Published
2015

39. Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol

Author

Yushkevich, Paul A, Amaral, Robert SC, Augustinack, Jean C, Bender, Andrew R, Bernstein, Jeffrey D, Boccardi, Marina, Bocchetta, Martina, Burggren, Alison C, Carr, Valerie A, Chakravarty, M Mallar, Chételat, Gaël, Daugherty, Ana M, Davachi, Lila, Ding, Song-Lin, Ekstrom, Arne, Geerlings, Mirjam I, Hassan, Abdul, Huang, Yushan, Iglesias, J Eugenio, La Joie, Renaud, Kerchner, Geoffrey A, LaRocque, Karen F, Libby, Laura A, Malykhin, Nikolai, Mueller, Susanne G, Olsen, Rosanna K, Palombo, Daniela J, Parekh, Mansi B, Pluta, John B, Preston, Alison R, Pruessner, Jens C, Ranganath, Charan, Raz, Naftali, Schlichting, Margaret L, Schoemaker, Dorothee, Singh, Sachi, Stark, Craig EL, Suthana, Nanthia, Tompary, Alexa, Turowski, Marta M, Van Leemput, Koen, Wagner, Anthony D, Wang, Lei, Winterburn, Julie L, Wisse, Laura EM, Yassa, Michael A, Zeineh, Michael M, and Group, for the Hippocampal Subfields

Subjects
Biomedical and Clinical Sciences, Biomedical Imaging, Neurosciences, Adult, Clinical Protocols, Hippocampus, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Parahippocampal Gyrus, Medial temporal lobe, Hippocampal subfields, CA1, CA2, CA3, Dentate gyrus, Subiculum, Entorhinal cortex, Perirhinal cortex, Parahippocampal gyrus, Magnetic resonance imaging, Segmentation, Unified protocol, Hippocampal Subfields Group, Medical and Health Sciences, Psychology and Cognitive Sciences, Neurology & Neurosurgery, Biomedical and clinical sciences, Health sciences
Abstract

ObjectiveAn increasing number of human in vivo magnetic resonance imaging (MRI) studies have focused on examining the structure and function of the subfields of the hippocampal formation (the dentate gyrus, CA fields 1-3, and the subiculum) and subregions of the parahippocampal gyrus (entorhinal, perirhinal, and parahippocampal cortices). The ability to interpret the results of such studies and to relate them to each other would be improved if a common standard existed for labeling hippocampal subfields and parahippocampal subregions. Currently, research groups label different subsets of structures and use different rules, landmarks, and cues to define their anatomical extents. This paper characterizes, both qualitatively and quantitatively, the variability in the existing manual segmentation protocols for labeling hippocampal and parahippocampal substructures in MRI, with the goal of guiding subsequent work on developing a harmonized substructure segmentation protocol.MethodMRI scans of a single healthy adult human subject were acquired both at 3 T and 7 T. Representatives from 21 research groups applied their respective manual segmentation protocols to the MRI modalities of their choice. The resulting set of 21 segmentations was analyzed in a common anatomical space to quantify similarity and identify areas of agreement.ResultsThe differences between the 21 protocols include the region within which segmentation is performed, the set of anatomical labels used, and the extents of specific anatomical labels. The greatest overall disagreement among the protocols is at the CA1/subiculum boundary, and disagreement across all structures is greatest in the anterior portion of the hippocampal formation relative to the body and tail.ConclusionsThe combined examination of the 21 protocols in the same dataset suggests possible strategies towards developing a harmonized subfield segmentation protocol and facilitates comparison between published studies.

Published
2015

42. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

Author

van Maurik, Ingrid S, Vos, Stephanie J, Bos, Isabelle, Bouwman, Femke H, Teunissen, Charlotte E, Scheltens, Philip, Barkhof, Frederik, Frolich, Lutz, Kornhuber, Johannes, Wiltfang, Jens, Maier, Wolfgang, Peters, Oliver, Rüther, Eckart, Nobili, Flavio, Frisoni, Giovanni B, Spiru, Luiza, Freund-Levi, Yvonne, Wallin, Asa K, Hampel, Harald, Soininen, Hilkka, Tsolaki, Magda, Verhey, Frans, Kłoszewska, Iwona, Mecocci, Patrizia, Vellas, Bruno, Lovestone, Simon, Galluzzi, Samantha, Herukka, Sanna-Kaisa, Santana, Isabel, Baldeiras, Ines, de Mendonça, Alexandre, Silva, Dina, Chetelat, Gael, Egret, Stephanie, Palmqvist, Sebastian, Hansson, Oskar, Visser, Pieter Jelle, Berkhof, Johannes, and van der Flier, Wiesje M

Published
2019
Full Text
View/download PDF

46. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need

Author

Babulal, Ganesh M., Quiroz, Yakeel T., Albensi, Benedict C., Arenaza-Urquijo, Eider, Astell, Arlene J., Babiloni, Claudio, Bahar-Fuchs, Alex, Bell, Joanne, Bowman, Gene L., Brickman, Adam M., Chételat, Gaël, Ciro, Carrie, Cohen, Ann D., Dilworth-Anderson, Peggye, Dodge, Hiroko H., Dreux, Simone, Edland, Steven, Esbensen, Anna, Evered, Lisbeth, Ewers, Michael, Fargo, Keith N., Fortea, Juan, Gonzalez, Hector, Gustafson, Deborah R., Head, Elizabeth, Hendrix, James A., Hofer, Scott M., Johnson, Leigh A., Jutten, Roos, Kilborn, Kerry, Lanctôt, Krista L., Manly, Jennifer J., Martins, Ralph N., Mielke, Michelle M., Morris, Martha Clare, Murray, Melissa E., Oh, Esther S., Parra, Mario A., Rissman, Robert A., Roe, Catherine M., Santos, Octavio A., Scarmeas, Nikolaos, Schneider, Lon S., Schupf, Nicole, Sikkes, Sietske, Snyder, Heather M., Sohrabi, Hamid R., Stern, Yaakov, Strydom, Andre, Tang, Yi, Terrera, Graciela Muniz, Teunissen, Charlotte, Melo van Lent, Debora, Weinborn, Michael, Wesselman, Linda, Wilcock, Donna M., Zetterberg, Henrik, and O'Bryant, Sid E.

Published
2019
Full Text
View/download PDF

49. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

Author

Mattsson, Niklas, Groot, Colin, Jansen, Willemijn J., Landau, Susan M., Villemagne, Victor L., Engelborghs, Sebastiaan, Mintun, Mark M., Lleo, Alberto, Molinuevo, José Luis, Jagust, William J., Frisoni, Giovanni B., Ivanoiu, Adrian, Chételat, Gaël, Resende de Oliveira, Catarina, Rodrigue, Karen M., Kornhuber, Johannes, Wallin, Anders, Klimkowicz-Mrowiec, Aleksandra, Kandimalla, Ramesh, Popp, Julius, Aalten, Pauline P., Aarsland, Dag, Alcolea, Daniel, Almdahl, Ina S., Baldeiras, Inês, van Buchem, Mark A., Cavedo, Enrica, Chen, Kewei, Cohen, Ann D., Förster, Stefan, Fortea, Juan, Frederiksen, Kristian S., Freund-Levi, Yvonne, Gill, Kiran Dip, Gkatzima, Olymbia, Grimmer, Timo, Hampel, Harald, Herukka, Sanna-Kaisa, Johannsen, Peter, van Laere, Koen, de Leon, Mony J., Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Møllergård, Hanne M., Morris, John C., Mroczko, Barbara, Nordlund, Arto, Prabhakar, Sudesh, Peters, Oliver, Rami, Lorena, Rodríguez-Rodríguez, Eloy, Roe, Catherine M., Rüther, Eckart, Santana, Isabel, Schröder, Johannes, Seo, Sang W., Soininen, Hilkka, Spiru, Luiza, Stomrud, Erik, Struyfs, Hanne, Teunissen, Charlotte E., Verhey, Frans R.J., Vos, Stephanie J.B., van Waalwijk van Doorn, Linda J.C., Waldemar, Gunhild, Wallin, Åsa K., Wiltfang, Jens, Vandenberghe, Rik, Brooks, David J., Fladby, Tormod, Rowe, Christopher C., Drzezga, Alexander, Verbeek, Marcel M., Sarazin, Marie, Wolk, David A., Fleisher, Adam S., Klunk, William E., Na, Duk L., Sánchez-Juan, Pascual, Lee, Dong Young, Nordberg, Agneta, Tsolaki, Magda, Camus, Vincent, Rinne, Juha O., Fagan, Anne M., Zetterberg, Henrik, Blennow, Kaj, Rabinovici, Gil D., Hansson, Oskar, van Berckel, Bart N.M., van der Flier, Wiesje M., Scheltens, Philip, Visser, Pieter Jelle, and Ossenkoppele, Rik

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results